Mark Allen Bach - 15 Mar 2024 Form 4/A Insider Report for Structure Therapeutics Inc. (GPCR)

Reporting relationship: CHIEF MEDICAL OFFICER
Issuer ticker: GPCR
Reported as of: 15 Mar 2024
Net transaction value: $0
SEC form: 4/A
Accepted by SEC: 20 Mar 2024, 19:41:13 UTC
Original report date: 19 Mar 2024
Prior SEC filing: 09 Feb 2023
Source filing: View source filing
Reporting owner signature: /s/ Jun Yoon, Attorney-in-Fact

Key filing fact

Mark Allen Bach filed Form 4/A for Structure Therapeutics Inc. (GPCR) on 20 Mar 2024.

Key facts

This page summarizes Mark Allen Bach's Form 4/A filing for Structure Therapeutics Inc. (GPCR).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 20 Mar 2024, 19:41.

Change

Previous filing in this sequence was filed on 09 Feb 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

GPCR transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +65,352
Change %
Price: $0.000000
Shares after: 65,352
Date: 15 Mar 2024
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 65,352
Exercise price: $11.75
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

This amendment is being filed to correct the exercise price as that of the Ordinary Shares rather than the American Depositary Shares ("ADSs"). The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's ADSs.

Footnote F2

1/4th of the shares subject to the option shall vest March 1, 2025, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each such vesting date.

Footnote F3

The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer.